A Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of Relapse
Recruiting · NCT05732974 · Observational (researchers observe without assigning treatment) · Lead sponsor: University Hospital, Toulouse
View the official record on ClinicalTrials.gov →Interventions studied
Resected non small cell lung cancer
What this trial is about
Early-stage non small cell lung cancer represents 20-30% of all non small cell lung cancer and is characterized by a high survival probability after surgical resection. However, considering stage IA-IIIA non small cell lung cancer, a relapse rate of about 50% is observed, with a different survival probability on the basis of tumor node metastasis status, although patients within the same tumor node metastasis stage exhibit wide variations in recurrence rate. There are currently no validated prognostic biomarkers able to identify patients with a high risk of relapse.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Patient with an early stage of non small cell lung cancer
- Indication of surgical resection
- Patient able to understand and give his consent
- Patient affiliated to the health insurance
Exclusion criteria
- Patient with another cancer in the last 5 years
- Patient with an allergy to the contrast medium
- Patient under legal protection
Where it is running
1 location listed.
- Julien MAZIERES - Toulouse, France